Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

Andrew M. Stein,Giovanni Martinelli,Timothy P. Hughes,Martin C. Müller,Lan Beppu,Enrico Gottardi,Susan Branford,Simona Soverini,Richard C. Woodman,Andreas Hochhaus,Dong-Wook Kim,Giuseppe Saglio,Jerald P. Radich

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

2013

Andrew M. Stein
Giovanni Martinelli
Timothy P. Hughes
Martin C. Müller
Lan Beppu
Enrico Gottardi
Susan Branford
Simona Soverini
Richard C. Woodman
Andreas Hochhaus
Dong-Wook Kim
Giuseppe Saglio
Jerald P. Radich

Background We evaluated BCR-ABL1 kinetics in patients treated with nilotinib and analyzed whether a dynamic model of changes in BCR-ABL1 levels over time could be used to predict long-term responses.

Keywords:

Pathology
Molecular Response
Cancer research
Stem cell
Chronic phase chronic myeloid leukemia
ABL
Nilotinib
Survival rate
Medicine
Surgical oncology
breakpoint cluster region
Imatinib
second line
Myeloid leukemia
bcr abl1
in patient
response type

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations